About 30% of all progressive memory disorders belong to the FTLD group.
In about 50% of patients, excluding those with FTLD plus syndromes, there is a positive family history.
The most common genetic aetiology associated with frontotemporal lobar degeneration is a non-coding repeat expansion of the C9orf72 (chromosome 9 open-reading frame 72) gene.
Study of the C9orf72 mutation may be beneficial for the diagnosis of these diseases.
FTLD patients of non-Finnish origin commonly have mutations in GRN and MAPT genes, as well.
Genetic testing is done in specialized care.
As frontotemporal lobar degeneration may have several underlying neuropathological subtypes, there are no specific biomarkers available for the disease.
CSF biomarker (tau, p-tau and amyloid β) tests used for the diagnosis of Alzheimer's disease do not reliably distinguish between frontotemporal lobar degeneration and Alzheimer's disease.
Normal findings in conventional cognitive screening tests (CERAD and MMSE) do not exclude diseases of the FTLD group.
The disease should primarily be diagnosed and treatment started by a neurologist, geriatrician or other physician with expertise in memory disorders.
Frontotemporal dementia
Accounts for about half of all cases of FTLD.
Disease onset usually occurs between the ages of 45 and 65.
Hereditary disease, in particular, may begin as early as at the age of 30.
FTLD with onset after the age of 70 is not rare, either.
The average duration of the disease is 8 years but there is substantial variation (2-20 years).
Typical clinical features:
Changes in behaviour and personality (disinhibition, impulsiveness, tactlessness, impaired judgement)
Problems with executive functions (planning, ability to concentrate, attention)
Atrophy in the frontal and/or temporal lobes can be detected by magnetic resonance imaging (MRI) of the brain, and functional imaging techniques (PET, SPECT) can detect corresponding hypoperfusion and hypometabolism.
In early and moderately severe disease, imaging may give normal findings.
Alzheimer's drugs are contraindicated, as they often aggravate the clinical picture.
Symptomatic treatment
Usual treatment of psychotic and affective symptoms
Antipsychotics, in particular, should be used at the lowest possible doses, as the patients are sensitive to extrapyramidal adverse effects.
Benzodiazepines should mostly be avoided since the disease pathology involves damage to the gamma-aminobutyric acid system.
Regular assessment of driving ability and legal competence
Ensuring a well-balanced diet and treatment of any deficiencies
The disease is often complicated by other problems associated with general care.